{
    "nct_id": "NCT03113500",
    "official_title": "A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients With CD30-Positive Peripheral T-Cell Lymphomas",
    "inclusion_criteria": "* Documented informed consent of participant and/or legally authorized representative\n* Agreement to allow the use of archival tissue from diagnostic tumor biopsies will be retrieved and submitted post-enrollment\n\n  * If unavailable, exceptions may be granted with study principal investigator (PI) approval.\n* Eastern Cooperative Oncology Group (ECOG) status =< 2\n* Histologically confirmed mature peripheral T-cell or natural killer (NK)-cell lymphoma per World Health Organization (WHO) classification, including:\n\n  * Anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) with international protein index (IPI) of 2 or higher (must have bulky [defined as mass >= 10 cm] stage II, or stage III-IV disease)\n  * ALK-negative ALCL\n\n    * NOTE: Per amendment dated 05-10-19, ALCL will no longer be eligible except for Canada.\n  * PTCL-not otherwise specified (NOS)\n  * Angioimmunoblastic T-cell lymphoma (AITL)\n  * Adult T-cell lymphoma/leukemia (ATLL)\n  * Enteropathy-associated T-cell lymphoma (EATL)\n  * Hepatosplenic T-cell lymphoma\n* CD30-positivity (e.g. at least 1%) by immunohistochemistry confirmed by hematopathology review at the participating institution\n* Measurable disease of at least 1.5 cm on computed tomography (CT) or positron emission tomography (PET)-CT scan\n* Absolute neutrophil count (ANC) >= 1,000/mm^3\n\n  * Exception: unless documented bone marrow involvement by lymphoma\n* Platelets >= 50,000/mm^3\n\n  * Exception: unless documented bone marrow involvement by lymphoma\n* Total serum bilirubin =< 1.5 x upper limit of normal (ULN) OR if hepatic involvement by lymphoma: =< 3 x ULN for Gilbert's disease or documented hepatic involvement by lymphoma\n* Aspartate aminotransferase (AST) =< 2 x ULN OR if hepatic involvement by lymphoma: AST =< 5 x ULN\n* Alanine aminotransferase (ALT) =< 2 x ULN OR if hepatic involvement by lymphoma: ALT =< 5 x ULN\n* Creatinine clearance of >= 60 mL/min per the Cockcroft-Gault formula\n* Left ventricular ejection fraction (LVEF) >= 45%\n* Women of childbearing potential (WOCBP): negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n* Agreement by WOCBP and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 months after the last dose of protocol therapy; childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior treatment of PTCL with systemic anti-lymphoma therapies, investigational agents, radiation\n\n  * Exception: May have received 1 cycle of CHOP-like therapy (e.g. CHOP, CHOEP, EPOCH) or 1 cycle of CHP-BV; these participants must initiate day 1 cycle 1 of study therapy (CHEP-BV) no less than 19 days from prior CHOP-like or CHP-BV therapy; Patients who received 1 cycle of CHOP-like or 1 cycle of CHP-BV therapy prior to initiating induction with CHEP-BV are allowed to receive only 5 cycles of CHEP-BV instead of 6 cycles, per investigator's discretion\n* History of another primary invasive cancer, hematologic malignancy, or myelodysplastic syndrome that has not been in remission for at least 3 years.\n\n  * Exceptions: Non-melanoma skin cancer and in situ cervical cancer\n* Symptomatic cardiac disease (including symptomatic ventricular dysfunction, symptomatic coronary artery disease, and symptomatic arrhythmias), cerebrovascular event/stroke or myocardial infarction within the past 6 months\n* Central nervous system involvement by lymphoma, including leptomeningeal involvement\n* History of progressive multifocal leukoencephalopathy (PML)\n* Active >= grade 3 viral, bacterial, or fungal infection within 2 weeks prior to day 1 of protocol therapy\n* Any known human immunodeficiency virus (HIV) infection, hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infection\n* Baseline peripheral neuropathy >= grade 2 or patients with the demyelinating form of Charcot-Marie-Tooth syndrome\n* Known severe hypersensitivity to any study related agent excipient(s)\n* Females only: pregnant or breastfeeding\n* Any other condition that would, in the investigator's judgement, contraindicate the patient's participation in the clinical study\n* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",
    "miscellaneous_criteria": ""
}